Lenskart IPO Day 1: Check Subscription Status, Key Highlights, and More

31 October 2025
1 min read
Lenskart IPO Day 1: Check Subscription Status, Key Highlights, and More
whatsapp
facebook
twitter
linkedin
telegram
copyToClipboard

India’s eyewear retailer Lenskart Solutions' Initial Public Offering (IPO) is open for public subscription today, October 31, 2025.  One day before the IPO opening, the company raised ₹3,268 crore from anchor investors on October 30, 2025. 

Lenskart IPO: Issue Details

Lenskart's IPO is a book-building issue of ₹7,278.02 crores, comprising a fresh issue of ₹2,150.00 crores and an offer-for-sale of ₹5,128.02 crores by promoters and investors.  

The price band is set between ₹382 and ₹402 per share. The basis of allotment will be finalised by November 6, 2025, and the tentative listing date on BSE and NSE is November 10, 2025. 

Lenskart IPO Day 1 Subscription Status

[31-October-2025 10:54:00 hrs]

Investor Category

Subscription (Times)

Qualified Institutional Buyers (QIBs)

0.00

Non-Institutional Investors

0.07

Retail Individual Investors (RIIs)

0.34

Employees

0.26

Total

0.08

Utilisation of IPO Proceeds

The net proceeds from the fresh will be used to 

  • Fund capital expenditure towards the set-up of new CoCo stores in India and lease/rent/licence agreement-related payments for CoCo stores
  • Brand marketing and business promotion activities
  • Invest in tech and cloud infrastructure
  • Unidentified inorganic acquisitions 
  • General corporate purposes 

Lenskart Business Overview

Lenskart is engaged in the business of designing, manufacturing, branding and retailing eyewear products. Their product portfolio includes prescription eyeglasses, sunglasses, and other products such as contact lenses and eyewear accessories. 

According to the Redseer Report, Lenskart is India’s largest and one of Asia’s two largest organised retailers of prescription eyeglasses by B2C sales volume in FY2025. 

Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.

To read the RA disclaimer, please click here

Do you like this edition?